Legal & General Group
DMAC icon

Legal & General Group’s DiaMedica Therapeutics DMAC Stock Holding History

Legal & General Group’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.2K Sell
2,986
-539
-15% -$4.27K ﹤0.01% 2959
2025
Q4 		$28.1K Hold
3,525
– – ﹤0.01% 2899
2025
Q3 		$24.2K Buy
3,525
+582
+20% +$3.16K ﹤0.01% 2966
2025
Q2 		$11.5K Buy
+2,943
New +$11.5K ﹤0.01% 3233

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Legal & General Group's DMAC Position: Q1 2026 in Review

Legal & General Group reduced its DiaMedica Therapeutics (DMAC) stake by 15% in Q1 2026, selling an estimated $4.27K and leaving 2,986 shares worth $20.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2959.

Legal & General Group first reported a position in DMAC in Q2 2025 and has held it in 4 quarters since. The position peaked at $28.1K in Q4 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Legal & General Group held 2,986 shares of DiaMedica Therapeutics worth $20.2K as of Q1 2026.
  • Legal & General Group sold 539 DiaMedica Therapeutics shares in Q1 2026, an estimated $4.27K.
  • DiaMedica Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2959 holding.
  • Legal & General Group first reported a position in DiaMedica Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Legal & General Group's DiaMedica Therapeutics position peaked at $28.1K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.